These data reveal PRC2 and ERK1/2 to be negative regulators of Utrn expression and provide specialised molecular imaging tools to monitor utrophin expression as a therapeutic strategy for DMD. This evidence concerns the gene MAPK3 and Duchenne muscular dystrophy.